Bimatoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bimatoprost: From Glaucoma/Eyelash Hypotrichosis to Alopecia (Androgenetic & Areata)
One-Sentence Summary
Bimatoprost is a synthetic prostamide F2α analog originally developed for glaucoma/ocular hypertension and later approved internationally for eyelash hypotrichosis (Latisse™). Among the ten indications TxGNN predicted for this drug, most are top-score but mechanistically implausible "knowledge-graph noise" (e.g., periodontal malformation syndromes, Dandy-Walker malformation, pulmonary AV malformation) with zero supporting trials or literature. The one prediction with genuine, converging evidence is Alopecia (androgenetic and areata subtypes), supported by 11 clinical trials (5 graded "A" relevance) and 22 publications, making it the only candidate worth advancing.
⚠️ Note on prediction selection: The report below is built around Alopecia (rank 8) rather than the TxGNN top-ranked prediction (rank 1, "malformation syndrome with odontal/periodontal component"), because rank 1–6 and rank 10 are explicitly annotated in the evidence pack itself as mechanistically unrelated and evidence-free (score ≈99.99% but 0 trials, 0 relevant literature — classic embedding-space noise). Alopecia is the only prediction meeting a real decision-stage threshold (S2).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / Ocular Hypertension; Eyelash Hypotrichosis (international approval — not derived from local license data, which is absent) |
| Predicted New Indication | Alopecia (androgenetic alopecia, female pattern hair loss, alopecia areata) |
| TxGNN Prediction Score | 99.99% (rank 136 of prioritized candidates) |
| Evidence Level | L2 |
| Local Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the drug record (DrugBank MOA field is a data gap). Based on information recoverable from the evidence pack itself, bimatoprost is a synthetic prostamide F2α analog. Its approved ophthalmic use for glaucoma works by increasing aqueous humor outflow; its approved dermatologic use for eyelash hypotrichosis (Latisse™) works by prolonging the anagen (growth) phase of the eyelash hair cycle and increasing follicle density/diameter — an effect that was originally identified as a side effect in glaucoma patients using prostaglandin-analog eye drops.
This anagen-prolongation mechanism is not eyelash-specific: hair follicles in the scalp undergo the same growth-cycle biology. Multiple mechanistic and clinical studies in the evidence pack (PMID 23104985, PMID 28264599, PMID 29854658) directly describe bimatoprost's off-label extension from eyelash to scalp hair growth, and this has already been tested in dedicated Phase 2 trials for androgenetic alopecia (male and female pattern hair loss) and in smaller studies/case series for alopecia areata.
In short, the original indication (eyelash hypotrichosis) and the predicted new indication (scalp alopecia) share the same target tissue type and the same growth-cycle mechanism — this is a mechanistically coherent, clinically plausible repurposing hypothesis, not merely a statistical prediction. This distinguishes it sharply from the other TxGNN-ranked candidates in this evidence pack, which lack any mechanistic or tissue-level connection to prostamide biology.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02170662 | Phase 2 | Completed | 33 | Direct mechanistic test of bimatoprost solution on androgen-dependent scalp follicles |
| NCT01325350 | Phase 2 | Completed | 306 | 3 doses of bimatoprost vs. vehicle vs. OTC minoxidil 2% in women with female pattern hair loss |
| NCT01023841 | Phase 4 | Completed | 71 | Safety/efficacy of bimatoprost 0.03% for eyelash hypotrichosis in children — supports approved-indication safety extension |
| NCT01904721 | Phase 2 | Completed | 244 | Safety and efficacy of bimatoprost in men with androgenic alopecia (AGA) |
| NCT01325337 | Phase 2 | Completed | 307 | 3 doses of bimatoprost vs. vehicle vs. OTC minoxidil 5% in men with androgenic alopecia |
| NCT01189279 | Phase 1 | Completed | 42 | Safety and pharmacokinetics of new bimatoprost formulations in alopecia patients |
| NCT02848300 | Phase 1 | Completed | 11 | Local scalp pharmacokinetics/tolerability of two bimatoprost formulations in AGA |
| NCT05600673 | Phase 1/2 | Completed | 30 | Combined CO2 fractional laser + bimatoprost 0.03% for alopecia areata (adjunct therapy) |
| NCT00187577 | N/A | Completed | 14 | Randomized, investigator-masked comparison of latanoprost vs. bimatoprost for eyelash regrowth in alopecia areata |
| NCT02676310 | Phase 1 | Terminated | 53 | Dose-escalation safety/PK study of bimatoprost topical solution in male AGA (terminated, incomplete data) |
(One additional trial, NCT00999557, was withdrawn with zero enrollment and is excluded above.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32250713 | 2022 | Review/Network Meta-analysis (Tier 1) | J Dermatol Treat | Systematic comparison of non-surgical AGA monotherapies; contextualizes bimatoprost among evidence-graded options |
| 29863806 | 2018 | Guideline (Tier 1) | J Dermatol | Japanese guidelines for diagnosis/treatment of male- and female-pattern hair loss |
| 28264599 | 2017 | Review | Expert Opin Investig Drugs | Comprehensive review of bimatoprost for eyelash, eyebrow, and scalp alopecia |
| 23104985 | 2013 | Review | FASEB J | Original rationale paper proposing prostamide-based glaucoma therapy (bimatoprost) as a novel scalp alopecia treatment |
| 40252129 | 2025 | Cohort | Arch Dermatol Res | CO2 fractional laser + bimatoprost combination therapy improves hair regrowth in alopecia areata |
| 35278027 | 2022 | Cohort/Prospective open-label | Dermatol Ther | Topical bimatoprost for eyelash loss in alopecia totalis/universalis; 16/[cohort] responders reported |
| 32642317 | 2020 | Review | Dermatol Pract Concept | Review of prevention/treatment options for chemotherapy-induced alopecia, including bimatoprost |
| 34304865 | 2021 | Review | Bull Cancer | Alopecia pathophysiology and treatment pathways in oncology settings |
| 37185388 | 2023 | Review | Curr Oncol | Prevention/treatment landscape for chemotherapy-induced alopecia |
| 27377163 | 2016 | Case Report | Pediatr Dermatol | Successful treatment of steroid-resistant pediatric scalp alopecia areata with topical bimatoprost |
Local Market Information
Bimatoprost currently holds 0 authorizations and is not marketed in this jurisdiction (taiwan_regulatory.market_status = 未上市). No license records are available to summarize approved indications, dosage forms, or product names.
Safety Considerations
Please refer to the package insert for safety information. No structured warnings, contraindications, or drug-drug interaction data were retrievable at this time (safety.key_warnings, safety.contraindications, and safety.ddi are all marked as data gaps in the source pack).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The Alopecia indication is supported by an L2 evidence level — multiple completed Phase 2 RCTs (n=244–307) directly testing bimatoprost against vehicle and active comparator (minoxidil) in both male AGA and female pattern hair loss, plus a plausible, biologically grounded mechanism already validated in the drug's approved eyelash-growth indication. This is a categorically different evidence profile from the other nine TxGNN predictions in this pack, which have zero trials, zero literature, and no coherent mechanistic rationale.
To proceed, the following is needed:
- Retrieve TFDA/local regulatory label (warnings, contraindications) — currently a Blocking data gap (DG001)
- Confirm formal mechanism-of-action documentation via DrugBank API — currently a High severity data gap (DG002)
- Formal review of the four completed Phase 2 AGA/FPHL trial results (efficacy endpoints, adverse events) before any regulatory or clinical-use recommendation
- Given no local marketing authorization exists, any advancement would require a full new-indication filing pathway, not a label-extension pathway
- Do not pursue the remaining nine TxGNN-predicted indications (ranks 1–7, 9–10) without independent mechanistic validation — current evidence indicates they are graph-embedding artifacts rather than genuine repurposing signals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.